Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Study design is a Phase IIb prospective multi-center, randomized, placebo-controlled,
double-blind clinical trial. The goal will be to enroll 80 infants with Tuberous Sclerosis
Complex who are less than 6 months of age prior to the onset of their first seizure
Phase:
Phase 2
Details
Lead Sponsor:
Martina Bebin
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)